CNS Pharma shareholders approve 12x increase in authorized common shares to 300M and equity plan expansion

CNS Pharmaceuticals, Inc.

Authorized common stock increased from 25M to 300M shares; preferred from 416,667 to 5M shares.
2020 Equity Plan shares authorized increased by 114,916 to total 115,061 shares.
All six director nominees elected: Climaco, Gumulka, Keyes, Charles, Cockroft, Mahery.
MaloneBailey LLP ratified as independent auditor for FY 2025; say-on-pay approved with annual frequency.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

CNS Pharmaceuticals, Inc.: Amended articles to increase authorized common stock from 25,000,000 shares to 300,000,000 shares and preferred stock from 416,667 shares to 5,000,000 shares (effective 2025-11-20).

Change: charter amendment
Effective: 2025-11-20

Exact text from the filing

On November 20, 2025, the Company filed a Certificate of Amendment to its Amended and Restated Articles of Incorporation (the “Amendment”) with the Secretary of State of the State of Nevada to increase the number of the Company’s authorized shares of common stock from 25,000,000 shares to 300,000,000 shares and to increase the total number of authorized shares of preferred stock from 416,667 shares to 5,000,000 shares.

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

CNS Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-25-008624

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.